Skip to main content

Open Access IL-1β-mediated NF-κB signaling augments the osteosarcoma cell growth through modulating miR-376c/TGFA axis

Overexpression of IL-1β, one of the most well-known pro-inflammatory cytokines, is related to a plenty of diseases including cancer. Diversion of microRNAs exposed to pro-inflammatory cytokines have been noted in cancer cells, however, their functions in inflammation stress are still to be further studied. In our previous study, we reported that miR-376c inhibited the growth of osteosarcoma (OS) cells by targeting TGFA. Here, we revealed that miR-376c was downregulated in OS tissues and cells while IL-1β, NF-κB and TGFA were upregulated in OS tissues and cells. IL-1β or NF-κB could promote the OS cells growth through inducing miR-376c expression and decreasing TGFA protein levels. Furthermore, forced expression of miR-376c restored the suppression of IL-1β on the OS cells. A decrease in miR-376c and an increase in TGFA depended on IL-1β-induced NF-κB protein level, which attenuates miR-376c expression upon IL-1β reduction. Taken together, our findings indicated that IL-1β augmented miR-376c-reduction to promote OS cell growth via upregulating NF-κB levels. Knock-down NF-κB suppressed the expression of TGFA. Enhanced TGFA upon IL-1β induction was attenuated by NF-κB inhibition. Hence, the regulation of IL-1β/NF-κB/miR-376c/TGFA signaling in OS might present a promising strategy for the treatment of OS.

Document Type: Research Article

Publication date: 01 July 2017

More about this publication?
  • Pharmazie is a leading journal in the field of pharmaceutical sciences. As a peer-reviewed scientific journal, Pharmazie is regularly indexed in the relevant databases like Web of science, Journal Citation Reports and many others. The journal is open for submissions from the whole spectrum of pharnaceutical sciences including Pharmaceutical Chemistry, Experimental and Clinical Pharmacology, Drug Analysis, Pharmaceutics, Pharmaceutical Biology, Clinical Pharmacy etc.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content